recent
infecti
agent
includ
west
nile
viru
wnv
dengu
viru
chikungunya
viru
sever
acut
respiratori
syndrom
sar
viru
middleeast
coronaviru
variou
avian
flu
virus
pandem
potenti
ebola
viru
ebov
transfus
convalesc
blood
product
may
consid
treat
patient
affect
emerg
infecti
agent
specif
treatment
yet
avail
infect
gener
effect
protect
antibodi
transfus
convalesc
blood
product
demonstr
efficaci
fight
variou
viral
bacteri
infecti
diseas
includ
influenza
measl
chickenpox
recent
sar
avian
flu
virus
convalesc
blood
product
obtain
collect
blood
plasma
donor
prefer
live
geograph
infect
area
account
potenti
mutat
viru
surviv
previou
infect
develop
antibodi
convalesc
blood
product
transfus
achiev
passiv
immun
recipi
neutral
pathogen
eventu
lead
erad
blood
circul
ebov
member
famili
filovirida
recent
exampl
infecti
outbreak
affect
west
african
countri
absenc
licens
therapeut
product
yet
vaccin
antivir
treatment
world
health
organ
recent
approv
principl
evalu
certain
condit
control
clinic
studi
would
evalu
safeti
efficaci
absenc
current
altern
use
convalesc
serum
first
therapeut
option
treat
patient
ebov
part
decis
reli
histor
data
use
convalesc
blood
product
variou
infect
report
found
infus
convalesc
whole
blood
associ
surviv
seven
eight
ebola
patient
democrat
republ
congo
heattreat
convalesc
ebola
serum
infus
togeth
human
interferon
research
investig
accident
infect
ebov
anim
studi
suggest
potenti
protect
effect
antiebov
antibodi
individu
surviv
previou
infecti
outbreak
possibl
donor
convalesc
blood
potenti
contain
protect
longlast
immunoglobulin
ig
serolog
crossreact
variou
ebov
strain
found
may
potenti
increas
number
potenti
donor
treat
peopl
affect
recent
outbreak
stage
efficaci
safeti
transfus
ebola
convalesc
blood
product
fulli
proven
although
suspect
may
help
treatment
suggest
antibodydepend
enhanc
ade
filoviru
infect
may
risk
clinic
relev
ade
controversi
document
attempt
clarifi
type
convalesc
blood
product
consid
treat
patient
ebov
gener
viral
infect
use
animalderiv
serum
human
convalesc
blood
product
first
report
earli
centuri
treat
variou
infect
vaccin
treatment
antibiot
yet
avail
mani
report
lack
import
technic
inform
product
prepar
procedur
term
use
may
mislead
eg
term
serum
may
employ
gener
way
design
blood
product
use
convalesc
whole
blood
serum
obtain
let
blood
clot
report
influenza
see
ref
mump
herp
zoster
poliomyel
typhoid
fever
measl
earli
clinic
exampl
whole
blood
convert
serum
allow
clot
describ
treat
measl
patient
inject
intramuscular
rout
altern
serum
obtain
ad
calcium
chlorid
pool
sterilefilt
citrat
anticoagul
may
ad
blood
plasma
recov
decant
centrifug
use
convalesc
defibrin
plasma
describ
case
chickenpox
modern
blood
transfus
allow
prepar
rang
product
known
control
safeti
prepar
follow
standard
monitor
procedur
kept
mind
even
countri
advanc
bloodcollect
organ
collect
convalesc
blood
product
epidem
crisi
creat
substanti
organiz
difficulti
therefor
requir
adequ
prepar
collect
convalesc
bloodplasma
lowincom
economi
suscept
affect
devast
epidem
face
major
organiz
technolog
human
challeng
includ
control
convalesc
donor
clinic
viral
free
infect
pathogen
test
eg
human
immunodefici
viru
hepat
b
viru
hepat
c
viru
malaria
agent
syphili
temperatur
control
product
chain
process
traceabl
figur
summar
technic
option
consid
prepar
convalesc
blood
product
report
convalesc
whole
blood
use
democrat
republ
congo
treat
eight
ebola
patient
seven
surviv
although
high
rate
surviv
could
necessarili
ascertain
relat
blood
transfus
optim
effect
control
hemorrhag
event
may
occur
ebov
diseas
whole
blood
collect
anticoagul
solut
transfus
within
h
maintain
viabl
platelet
clot
factor
impli
viral
test
abo
rhd
crossmatch
immunohematolog
compat
test
perform
within
period
donor
prescreen
prior
donat
whole
blood
also
store
sever
day
eg
day
collect
citrat
phosphat
dextros
ad
adenin
last
year
convalesc
plasma
blood
fraction
success
select
transfus
patient
affect
argentin
hemorrhag
fever
junin
viru
sar
also
report
administr
lassa
fever
convalesc
plasma
lfcp
hospit
patient
nigeria
appar
increas
efficaci
outcom
diseas
plasma
infus
earli
enough
diagnosi
plasma
obtain
centrifug
decant
whole
blood
apheresi
apheresi
prefer
mode
collect
sever
reason
larger
volum
collectedsess
possibl
frequent
donat
absenc
impact
hemoglobin
level
due
reinfus
red
blood
cell
singl
plasma
unit
sever
viral
inactiv
technolog
plasma
transfus
applic
singl
unit
develop
valid
licens
sever
countri
principl
use
viralinactiv
process
convalesc
plasma
prefer
technic
achiev
case
uncertainti
possibl
residu
virus
plasma
howev
substitut
good
donor
screen
optim
viral
test
licens
technolog
includ
treatment
methylen
bluelight
psoralen
ultraviolet
uv
riboflavinuv
reader
find
detail
review
address
technic
characterist
advantag
limit
technolog
appli
plasma
transfus
use
viralinactiv
process
photoinactiv
presenc
photosensit
requir
dedic
bag
treatment
system
specif
proprietari
illumin
machin
oper
receiv
appropri
train
need
procedur
knowledg
publish
data
rel
inactiv
ebov
use
technolog
although
method
tend
induc
loss
activ
coagul
factor
includ
factor
viii
fibrinogen
thought
affect
immunoglobulin
function
activ
solventdeterg
sd
filter
sdf
plasma
technolog
routin
use
one
blood
center
egypt
ml
plasma
transfus
viral
inactiv
singleus
cemark
bag
system
sd
use
tri
nbutyl
triton
sd
agent
elimin
oil
extract
filtrat
plasma
sterilefilt
onlin
dispens
storag
bag
freez
method
valid
ensur
inactiv
log
sever
envelop
virus
includ
hiv
within
minut
treatment
thought
like
hiv
hbv
hcv
ebov
envelop
virus
readili
inactiv
sd
treatment
liquid
heattreat
plasma
collect
bag
presenc
stabil
compat
transfus
describ
process
valid
inactiv
log
human
immunodefici
viru
hiv
log
hepat
hav
c
hac
model
virus
procedur
use
prepar
convalesc
scrub
typhu
plasma
test
hivinhibitori
action
patient
follow
earlier
studi
found
presenc
plasmaborn
factor
produc
scrubtyphu
infect
system
commerci
avail
could
implement
short
term
anoth
experiment
plasma
heattreat
min
use
random
clinic
evalu
assess
potenti
benefit
passiv
immunotherapi
seroposit
plasma
serial
transfus
made
aid
patient
first
studi
second
random
control
trial
patient
receiv
infus
heattreat
plasma
everi
day
period
everi
day
thereaft
care
taken
heattreat
procedur
minim
alter
eg
aggreg
protein
could
lead
possibl
advers
event
patient
experiment
process
allow
viral
remov
plasma
transfus
filtrat
nm
hollow
fiber
describ
remov
virus
larger
nm
without
substanti
affect
igg
content
size
ebov
approxim
nm
principl
ensur
remov
commerci
devic
applic
plasma
made
avail
yet
minipool
plasma
fraction
process
use
dispos
licens
cemark
product
devic
base
capryl
acid
precipit
purifi
viral
inactiv
immunoglobulin
develop
egypt
current
process
scale
l
allow
pool
approxim
plasma
donat
treatment
valid
inactiv
lipidenvelop
virus
confirm
observ
immunoglobulin
product
current
clinic
evalu
egypt
minipool
process
approach
need
small
product
area
equip
laminar
flow
cabinet
may
particularli
suit
prepar
igg
minipool
convalesc
plasma
within
reason
delay
minim
infrastructur
requir
two
type
largescal
product
theoret
consid
produc
convalesc
blood
product
industri
sd
plasma
pool
plasma
transfus
viral
inactiv
sd
treatment
requir
pharmaceuticalgrad
facil
prepar
consid
proven
robust
wide
rang
envelop
virus
sd
process
also
inactiv
ebov
viru
present
convalesc
plasma
pool
size
industri
sd
plasma
gener
rang
donor
depend
upon
manufactur
local
regul
address
risk
infecti
agent
eg
nonenvelop
plasmaborn
virus
inactiv
sd
treatment
knowledg
exampl
prepar
industri
sdtreat
convalesc
plasma
largescal
fraction
intraven
ig
normal
intraven
ig
ivig
prepar
fraction
larg
pool
typic
l
human
plasma
collect
approxim
donor
pool
size
obvious
larg
consid
due
difficulti
gener
enough
convalesc
plasma
facil
hyperimmun
ig
made
smaller
pool
l
plasma
donor
identifi
high
titer
specif
antibodi
licens
hyperimmun
igg
includ
antihbv
antitetanu
antirabi
anticytomegaloviru
antirhesu
immunoglobulin
typic
made
donor
immun
routin
vaccin
licens
vaccin
control
immun
protocol
hyperimmun
igg
also
experiment
produc
plasma
donor
immun
natur
infecti
rout
describ
instanc
malaria
commerci
igg
made
good
manufactur
practiceinspect
facil
follow
licens
product
method
subject
least
two
distinct
viralreduct
step
igg
made
convalesc
plasma
experiment
prepar
small
scale
treat
patient
sar
normal
ivig
prepar
made
plasma
fraction
industri
may
contain
substanti
level
antibodi
infecti
agent
collect
donor
happen
seroconvert
previou
infecti
outbreak
commerci
ivig
product
may
high
antibodi
titer
wnv
hav
measl
dengu
viru
made
plasma
collect
popul
includ
donor
natur
infect
vaccin
prepar
convalesc
igg
licens
facil
would
creat
specif
probabl
unsolv
gmp
good
manufactur
practic
issu
consid
strict
regulatori
requir
plasma
fraction
adher
particularli
regard
qualiti
safeti
plasma
fraction
product
largepool
product
either
industri
sd
plasma
ivig
countri
advanc
nation
regulatori
author
standard
guidelin
appli
licens
product
use
plasma
meet
strict
qualiti
specif
epidemiolog
surveil
donor
screen
viral
test
bloodplasma
process
storag
transport
traceabl
etc
convalesc
plasma
lowor
mediumincom
countri
unlik
meet
forese
futur
therefor
manufactur
largepool
antiebov
igg
sdtreat
industri
plasma
seem
challeng
consid
serious
high
mortal
rate
infect
import
patient
affect
ebov
urgent
given
chanc
receiv
safe
convalesc
blood
product
potenti
save
life
sever
product
divers
technolog
consid
prepar
convalesc
blood
bloodderiv
therapi
fight
ebov
emerg
infecti
agent
whole
blood
plasma
may
first
option
consid
approach
provid
prepar
ethic
control
condit
product
safe
convalesc
blood
product
reli
whenev
possibl
wellstructur
wellcoordin
nation
bloodcollect
organ
case
current
affect
countri
westafrica
structur
serv
technolog
platform
convalesc
blood
collect
safeti
consider
guarante
traceabl
choic
distinct
set
eg
remot
health
care
center
efficaci
modal
clinic
use
convalesc
blood
product
taken
grant
control
clinic
evalu
also
therefor
import
establish
safe
modal
treatment
provid
import
knowledg
treatment
futur
infecti
outbreak
convalesc
blood
product
prepar
use
strict
control
monitor
ensur
optim
safeti
donor
recipi
recent
publish
guidanc
document
provid
technic
inform
prepar
convalesc
blood
product
